JAK3 and TYK2 Serve as Prognostic Biomarkers and Are Associated with Immune Infiltration in Stomach Adenocarcinoma

Table 2

Correlation of JAK3/TYK2 mRNA expression and postprogression survival in STAD with different clinicopathological factors (Kaplan–Meier plotter).

Pathological parameters	Post progression survival
	JAK3			TYK2
		Hazard radio	value		Hazard radio	value
Sex
Female	149	1.84 (1.19-2.85)	0.0053	149	2.36 (1.49-3.73)	0.00015
Male	348	1.71 (1.31-2.22)	0.000055	348	2.32 (1.79-3.02)
Stage
1	31	2.86 (0.5-16.46)	0.22	31	1.66 (0.37-7.43)	0.51
2	105	2.5 (1.28-4.87)	0.0053	105	2.39 (1.23-4.64)	0.0081
3	142	1.45 (0.92-2.28)	0.1	142	2.47 (1.6-3.83)
4	104	1.66 (1.01-2.72)	0.045	104	0.68 (0.42-1.11)	0.12
Stage T
2	196	1.66 (1.05-2.64)	0.029	196	1.72 (1.09-2.73)	0.019
3	150	1.21 (0.8-1.82)	0.36	150	1.91 (1.17-3.12)	0.0083
4	29	0.45 (0.15-1.38)	0.15	29	0.61 (0.22-1.64)	0.32
Stage N
0	41	2.59 (0.72-9.35)	0.13	41	2.57 (0.77-8.57)	0.11
1	169	2.52 (1.6-3.98)	0.000039	169	2.48 (1.58-3.91)
2	105	0.7 (0.43-1.15)	0.16	105	1.67 (0.99-2.81)	0.054
3	63	1.65 (0.86-3.18)	0.13	63	0.53 (0.29-0.95)	0.032
1+2+3	337	1.44 (1.06-1.95)	0.02	337	1.62 (1.21-2.17)	0.0011
Stage M
0	342	1.38 (1-1.9)	0.051	342	1.91 (1.4-2.6)
1	36	2.35 (1.08-5.13)	0.028	36	0.73 (0.33-1.63)	0.44
Lauren classification
Intestinal	192	1.69 (1.08-2.66)	0.02	192	1.86 (1.22-2.84)	0.0037
Diffuse	176	1.5 (0.99-2.26)	0.053	176	1.55 (1.05-2.29)	0.028
Differentiation
Poor	49	3.3 (1.59-6.88)	0.00076	49	1.68 (0.82-3.41)	0.15
Moderate	24	2.06 (0.75-5.63)	0.15	24	0.63 (0.26-1.56)	0.32